E
Ekaterini Boleti
Researcher at Royal Free Hospital
Publications - 36
Citations - 2230
Ekaterini Boleti is an academic researcher from Royal Free Hospital. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 11, co-authored 22 publications receiving 1854 citations. Previous affiliations of Ekaterini Boleti include Institute of Cancer Research & University College London.
Papers
More filters
Journal ArticleDOI
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,David Cella,James Reeves,Robert E. Hawkins,Jun Guo,Paul Nathan,Michael Staehler,Paul de Souza,Jaime R. Merchan,Ekaterini Boleti,Kate Fife,Jie Jin,Robert Jones,Hirotsugu Uemura,Ugo De Giorgi,Ulrika Harmenberg,Jinwan Wang,Cora N. Sternberg,Keith C. Deen,Lauren McCann,Michelle D. Hackshaw,Rocco Crescenzo,Lini Pandite,Toni K. Choueiri +24 more
TL;DR: Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazoSmithKline Pharmaceuticals.
Journal ArticleDOI
The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer
Thomas Powles,Christian U. Blank,Simon Chowdhury,Simon Horenblas,John Peters,Jonathan Shamash,Naveed Sarwar,Ekaterini Boleti,Anju Sahdev,Tim O'Brien,Daniel M. Berney,Luis Beltran,Paul Nathan,John B. A. G. Haanen,Axel Bex +14 more
TL;DR: Upfront sunitinib prior to planned nephrectomy in intermediate-risk disease is associated with a median survival of >2 yr despite frequent progression during treatment break, and progression in metastatic sites prior toplanned surgery and MSKCC poor- risk disease was associated withA poor outcome.
Journal ArticleDOI
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Thomas Powles,Matthew Wheater,O.S. Din,T. Geldart,Ekaterini Boleti,Andrew Stockdale,Santhanam Sundar,Angus Robinson,Imtiaz Ahmed,Akhila Wimalasingham,Wendy Burke,Shah-Jalal Sarker,Syed A. Hussain,Christy Ralph +13 more
TL;DR: The PFS and OS of AZD2014 were inferior to everolimus in this setting despite acceptable AE and PK profiles, and there is a strong rationale for testing mTOR inhibitors with a broader spectrum of activity than everlimus in metastatic clear cell renal cell carcinoma.
Journal ArticleDOI
The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
Kevin Sharpe,Grant D. Stewart,Alan Mackay,Christophe Van Neste,Charlotte Rofe,Daniel M. Berney,Irfan Kayani,Axel Bex,Elaine Wan,Fiach C. O'Mahony,Marie O'Donnell,Simon Chowdhury,Rukma Doshi,Colan Ho-Yen,Marco Gerlinger,Dawn Baker,Neil Smith,Barry Davies,Anju Sahdev,Ekaterini Boleti,Tim De Meyer,Wim Van Criekinge,Luis Beltran,Yong-Jie Lu,David J. Harrison,Andrew R. Reynolds,Thomas Powles +26 more
TL;DR: Investigation of biologically relevant markers change in response to antiangiogenic therapy in metastatic clear cell renal cancer and correlate these changes with outcome indicates that treatment is associated with an increase in the aggressive phenotype of the tumor.
Journal ArticleDOI
Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer
Thomas Powles,Naveed Sarwar,Andrew Stockdale,Shah-Jalal Sarker,Ekaterini Boleti,Andrew Protheroe,Robert Jones,Simon Chowdhury,John Peters,Grenville Oades,Tim O'Brien,Mark Sullivan,Michael Aitchison,Luis Beltran,Daniel C Worth,Katherine Smith,Constance Michel,Giorgia Trevisan,Elizabeth Harvey-Jones,Akhila Wimalasingham,Anju Sahdev,Charlotte Ackerman,Simon J. Crabb +22 more
TL;DR: Nephrectomy after upfront pazopanib therapy could be performed safely and was associated with good outcomes in patients with intermediate-risk metastatic clear cell renal cancer.